Maveropepimut-s is a subunit vaccine commercialized by IMV, with a leading Phase II program in Diffuse Large B-Cell Lymphoma. According to Globaldata, it is involved in 16 clinical trials, of which 6 were completed, 5 are ongoing, 1 is planned, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Maveropepimut-s’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Maveropepimut-s is expected to reach an annual total of $71 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Maveropepimut-s Overview
Maveropepimut-s (DPX-Survivac) is under development for the treatment of glioblastoma, ovarian cancer, fallopian tube cancer, bladder cancer, liver cancer (hepatocellular carcinoma), non-small cell lung (NSCLC) cancer as well as tumors shown to be positive for the microsatellite instability-high (MSI-H) biomarker, diffuse large B-cell lymphoma, peritoneal cancer and (HR+/HER2-) breast cancer. It is administered subcutaneously. It comprises survivin-based antigens formulated in the DepoVax delivery platform and DPX platform. It was also under development for the treatment of prostate cancer.
See Also:
IMV Overview
IMV, formerly Immunovaccine Inc, is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver, non-small cell lung cancer and diffuse large B cell lymphoma (DLBCL); DPX-RSV for Respiratory Syncytial Virus (RSV); and DPX-Covid-19 for the treatment of coronavirus. It is also advancing DPX-SurMAGE against bladder cancer and DPX-BRAF to treat melanoma. IMV harnesses its proprietary DPX platform technology to deliver drugs. The company partners with pharmaceutical companies, academic research institutions and government agencies to research and develop therapies for cancer. IMV is headquartered in Dartmouth, Nova Scotia, Canada.
The company reported revenues of (US Dollars) US$0.3 million for the fiscal year ended December 2022 (FY2022), an increase of 75% over FY2021. The operating loss of the company was US$38.2 million in FY2022, compared to an operating loss of US$35.7 million in FY2021. The net loss of the company was US$38 million in FY2022, compared to a net loss of US$36.6 million in FY2021.
For a complete picture of Maveropepimut-s’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
“Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
